$451 million into two AI biotech companies in a single morning. @enveda closed a $311M Series E led by @CatalioCapital. Their PRISM platform identifies biologically active molecules made by plants, microbes, and the human body, then ranks them by therapeutic potential so Enveda's chemists can turn the best ones into oral medicines. Since 2019 that approach has produced 17 development candidates, three now in human trials. Two of those read out positively this year. ENV-294 improved eczema severity by 85% on average after 42 days in Phase 1b, with more data coming at EADV on October 1. ENV-308, based on a molecule the body releases during intense exercise, was well tolerated in 88 volunteers with a very clean GI profile, and it's being developed to help people keep weight off after stopping GLP-1s. ENV-6946 for inflammatory bowel disease is in Phase 1. Enveda has now raised more than $845M total, and @georgecpetro of Catalio joins the board. The syndicate is basically a who's who across tech and healthcare: Durable Capital Partners, ICONIQ, @lightspeedvp, Surveyor Capital, @TRowePrice, Digitalis Ventures, Alderline Group, and a sovereign wealth fund as new investors, alongside existing backers @BaillieGifford, @PremjiInvest, FPV Ventures, @trueventures, @KinnevikAB, Dimension, Lifeforce Capital, and @Lux_Capital. Alex Gorsky, former J&J CEO and now at ICONIQ and Alderline, is part of it too. @Basecamp_Res closed an oversubscribed $140M Series C led by @S32_VC, with Andy Conrad, former CEO of Verily, joining the board. Their EDEN models are trained on the Trillion Gene Atlas, biological data collected through benefit-sharing partnerships in more than 30 countries and built with partners including @nvidia, @AnthropicAI, @PacBio, and Ultima Genomics. First target is in vivo cell therapy: pairing EDEN-designed DNA with large serine recombinases to write complex sequences into a patient's cells inside the body, which could take a lot of the cost out of today's cell therapies. André Hoffmann, Vice-Chairman of @Roche, invested personally, and Richard Pearce joins from @biogen as Chief Business Officer. That round brought in Anthology Fund, @CatalioCapital, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, @nvidia, PostScriptum, Redalpine, @RockefellerFdn, Singular, Sovereign AI, and @trueventures. Reading the two announcements back to back, both companies are built on the same bet. The best starting material for new medicines is what evolution already made, and AI can finally read it at scale. Enveda cites an estimate that 99% of nature's chemical diversity has never been examined. That's the part I keep coming back to. Also kind of wild: Catalio and True Ventures are in both rounds, announced the same day. Congratulations to @viswacolluru, Nadeem Sarwar, Michael Charlton, Doug Maslin, Soumoditya Dey, and the whole Enveda team, and to @glen_gowers, Richard Pearce, and everyone at Basecamp Research.